Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q15843

UPID:
NEDD8_HUMAN

ALTERNATIVE NAMES:
Neddylin; Neural precursor cell expressed developmentally down-regulated protein 8; Ubiquitin-like protein Nedd8

ALTERNATIVE UPACC:
Q15843; Q3SXN8; Q6LES6

BACKGROUND:
The ubiquitin-like protein NEDD8, also referred to as Neddylin, plays a critical role in the regulation of the cell cycle and embryogenesis. It achieves this by conjugating to a limited number of cellular proteins, including cullins and p53/TP53, which is essential for the polyubiquitination and subsequent proteasomal degradation of cyclins and other regulatory proteins. The attachment of NEDD8 to p53/TP53 notably inhibits its transcriptional activity, highlighting its significance in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of NEDD8 opens up avenues for developing novel therapeutic approaches, especially in areas concerning cell cycle regulation and embryonic development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.